Website unlawfully selling versions of Novo Nordisk weight loss drugs gets USFDA warning
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-07-03 13:15 GMT | Update On 2024-07-03 13:15 GMT
Advertisement
The U.S. Food and Drug Administration (USFDA) said on tuesday it had issued a warning against a website called ozempen.com for illegally selling versions of weight-loss drugs of Novo Nordisk.
Increasing demand for Novo's Ozempic, Eli Lilly's Mounjaro, and other GLP-1 drugs that aid in weight loss has led to a burgeoning global market for counterfeit versions.
The FDA said the website was offering unapproved versions of obesity and diabetes drugs Ozempic and Wegovy.
"These products are only available pursuant to a prescription from a licensed practitioner," as per Reuters report , the health regulator said.
Last month, the World Health Organization issued warnings on fake drugs claiming to contain the active ingredient found in Ozempic and Wegovy.
Lilly and Novo have sued several entities to stop them from selling products claiming to contain the active ingredients tirzepatide and semaglutide that are used in their respective popular diabetes and weight-loss drugs.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.